AI Uncovers 3.1% Lung Cancer Misdiagnosis Rate in Study

AI Algorithm Identifies Significant Cancer Misdiagnoses

Caris Life Sciences, an AI-powered biotech and precision medicine company, has published groundbreaking research in JAMA Network Open demonstrating how artificial intelligence can uncover clinically significant misdiagnoses in lung cancer cases. The study, titled "An AI Approach to Differentiating Lung Squamous Cell Carcinoma From Metastases of Other Origins," builds on evidence showing the effectiveness of proprietary AI algorithms over traditional diagnostic procedures.

Study Methodology and Key Findings

The research examined nearly 4,000 cases submitted for molecular profiling with a presumed diagnosis of primary lung squamous cell carcinoma. Dr. Matthew Oberley, chief clinical officer and pathologist-in-chief at Caris Life Sciences, explained the diagnostic challenge: "This is a category of cancer that can be difficult to distinguish from metastatic SCCs originating from other sites in the body, as SCC can arise from many anatomic locations in humans."

By applying an AI-driven tissue-of-origin model alongside clinical, molecular and immunohistochemical evidence, researchers identified a meaningful subset of misdiagnosed cases. "123 out of 3,958 cases – approximately 3.1% – were ultimately determined to be misdiagnosed, representing SCC that had metastasized to the lung from other primary sites," Oberley said.

Diverse Origins of Misclassified Tumors

The misclassified tumors spanned multiple origins, including cutaneous, head and neck, urothelial, and thymic carcinomas. In most cases, the AI model's prediction was corroborated by additional orthogonal evidence such as genomic signatures, immunohistochemistry or clinical history. The study found that in roughly three-quarters of these cases, the corrected diagnoses aligned with known clinical or imaging findings, reinforcing the validity of the revised classification.

Clinical Impact on Treatment Decisions

The diagnostic corrections carry significant clinical implications. "Perhaps most clinically significant, in the majority of cases, the diagnostic changes would lead to different first-line treatment recommendations under established clinical guidelines," Oberley noted. "This highlights that even a relatively small misdiagnosis rate can have outsized implications for patient care, particularly when the tumor is initially perceived to be early-stage lung cancer but turns out to represent metastatic disease."

AI's Advantages Over Traditional Methods

The central advantage of AI in this context lies in its ability to synthesize complex, multidimensional data at scale. Traditional pathology relies on tumor appearance under the microscope and a limited set of biomarkers, with SCC looking similar regardless of its origin. AI, by contrast, integrates gene expression, genomic alterations and other molecular signals simultaneously, allowing it to detect patterns readily missed through conventional methods.

"AI excels in identifying subtle molecular 'signatures' that point to a tumor's origin, such as UV-induced mutations in skin cancers or pathogen-associated signals like human papilloma virus infection," Oberley continued. "These signals may be technically detectable by humans, if considered, but are rarely assessed comprehensively or in combination during routine workflows."

Systematic Quality Control Benefits

Another key strength is that AI operates as a consistent, always-on screening tool. In this study, the AI model was applied to every case undergoing molecular profiling, regardless of prior suspicion of misdiagnosis. "This is important because many diagnostic errors persist simply due to a lack of suspicion or incomplete clinical context," Oberley explained. "By flagging discordant cases systematically, AI introduces a form of quality control that functions independently of individual vigilance or experience."

Population-Scale Impact

At scale, even a modest misdiagnosis rate can translate into substantial numbers of patients receiving suboptimal care. "The study suggests that if similar rates hold broadly, thousands of patients each year could be affected by incorrect tumor classification in just one cancer subtype," Oberley said. "Deploying AI systematically across diagnostic workflows could, therefore, have a meaningful impact by reducing these errors and ensuring that more patients receive therapies aligned with the true biology of their disease."

Democratizing Advanced Diagnostics

The implications extend beyond individual diagnoses to overall efficiency and consistency of cancer care. By standardizing tumor origin evaluation across institutions and care settings, AI has the potential to reduce variability in diagnostic quality. This could prove particularly valuable in community settings or regions with limited subspecialty expertise, effectively democratizing access to advanced diagnostic capabilities.

Future of Precision Oncology

Widespread adoption of such technology could accelerate the shift toward precision oncology. "Accurate identification of tumor origin is foundational to selecting the appropriate oncology therapy, enrolling patients in clinical trials and predicting outcomes," Oberley concluded. "As AI becomes more integrated into routine care, it may correct errors and uncover previously unrecognized disease patterns, ultimately contributing to more personalized, data-driven cancer treatment at population scale."

---

Source: AI uncovers significant misdiagnoses in carcinoma type, study shows - HealthcareITNews